The n e w e ng l a n d j o u r na l of
clinical therapeutics
From the Department of Radiological
Sciences, University of California at Irvine,
Orange (S.C.G.); and the Department of
Radiology, Georgetown University Medi-
cal Center, Washington, DC (J.B.S.). Ad-
dress reprint requests to Dr. Goodwin at
the Department of Radiological Sciences,
University of California at Irvine, 101 The
City Dr. S., Rte. 140, Orange, CA 92868,
or at sgoodwin@uci.edu.
N Engl J Med 2009;361:690-7.
Copyright © 2009 Massachusetts Medical Society.
690
Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
m e dic i n e
Uterine Fibroid Embolization
Scott C. Goodwin, M.D., and James B. Spies, M.D., M.P.H.
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies,
the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines,
if they exist, are presented. The article ends with the authors’ clinical recommendations.
A 45-year-old, premenopausal black woman (gravida 3, para 2, with a history of one
spontaneous abortion) presents with menorrhagia and dysmenorrhea that has wors-
ened progressively over a period of 10 years. She does not wish to have any more
children. On physical examination, she has a firm, nontender, enlarged uterus. The
ovaries are not palpable. Laboratory tests in the past had revealed intermittent mild
anemia that was correctable with iron supplementation, but more severe anemia has
been noted recently, and she has had increasing difficulty managing her menstrual
bleeding. In-office ultrasound examinations have shown several intramural uterine
masses consistent with uterine fibroids that have been slowly increasing in size; the
largest measures 6.5 cm at the point of its greatest dimension. The adnexa are normal.
The patient’s gynecologist has recommended a hysterectomy. However, the patient
does not want to undergo a hysterectomy, and her gynecologist suggests uterine fi-
broid embolization as an alternative. She is referred to an interventional radiologist
who orders a magnetic resonance imaging (MRI) scan. The results of the MRI confirm
the ultrasound findings and rule out adenomyosis. The interventional radiologist
discusses with the patient uterine fibroid embolization as an alternative to hysterec-
tomy. What treatment should be recommended for this patient?
The Cl inic a l Probl em
Uterine fibroids are among the most common tumors of the female reproductive
tract that occur in premenopausal women. In one study of women 17 to 44 years
of age undergoing tubal sterilization, fibroids were found in 9% of whites and 16% of
blacks,1 although the prevalence is much higher on pathological examination after
hysterectomy.2 The overall incidence has been reported to be 29.7 per 1000 patient-
years, with considerable variation according to age3; in most studies, the peak inci-
dence has been shown to occur among women who are in their early to mid-40s.4,5
The risk of having fibroids is higher by a factor of three among blacks than among
whites.6
Although uterine fibroids are benign, they can cause considerable symptoms.
The most frequent symptom is menorrhagia, with iron-deficiency anemia often
occurring as a result. Dysmenorrhea, pelvic pain and pressure, dyspareunia, urinary
frequency and urgency, and other pelvic symptoms may occur. Symptoms are often
of sufficient severity to necessitate surgical intervention. Fibroids are the most
common indication for hysterectomy in the United States; a total of 300,000 hys-
terectomies to remove fibroids are performed each year. The overall cost of treat-
ing fibroids was estimated at $2.1 billion in 2000.7 More than 70% of those costs
were directly related to hysterectomy.
n engl j med 361;7  nejm.org  august 13, 2009
The New England Journal of Medicine
 clinical ther apeutics

Ovarian artery Ovarian artery

Intramural fibroid

Subserosal Submucosal
fibroid fibroid

Uterine artery Uterine artery

Figure 1. The Vascular Anatomy of Uterine Fibroids.

Most fibroids receive their blood supply from the uterine artery, which is a branch of the internal iliac artery. Addi-
tional supply from the ovarian artery is present in 5 to 10% of cases, and anastomoses between the left and right uter-
ine arteries and between the uterine and ovarian arteries are not rare.
COLOR FIGURE

Rev2 07/13/09
Author Dr. Goodwin
S t r ategie s a nd E v idence abut the endometrial
Fig # lining,
1 4
are associated with
heavy menstrual
Title bleeding, whereas the presence
Uterine leiomyomas are benign monoclonal tu- of large fibroids
ME or the overall enlargement of
mors of the uterus composed of smooth muscle the uterus is DE
associatedJarcho with local pressure, pain,
cells and an extracellular matrix of collagen, fibro- or compressiveArtisteffects.Daniel Muller
nectin, and proteoglycan.8 It is not known what Most fibroid tumors AUTHOR receive their blood sup-
PLEASE NOTE:
Figure has been redrawn and type has been reset
initiates fibroid genesis, although it is clear that ply from the uterine artery (Fig.carefully
Please check 1). Perfusion from
the growth of fibroids is affected by the presence the ovarian artery
Issue dateis seen in 5 to 10% of cases.
00-00-2009
of estrogen, progesterone, and a variety of growth Anastomoses between the left and right uterine
factors.9 A role for gonadal steroids is suggested arteries occur in about 10% of patients, and be-
by the fact that fibroids are not seen in children tween the uterine and ovarian arteries in 10 to
and tend to regress after menopause. 30%.10 The tumor is typically surrounded by a
As they grow, fibroids cause enlargement of dense arterial plexus, whereas the center of the
the uterus. Fibroids that are located in a submu- fibroid itself is relatively hypovascular.10
cosal position, as well as intramural fibroids that Uterine fibroid embolization is a percutaneous

n engl j med 361;7 nejm.org august 13, 2009 691

The New England Journal of Medicine
Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
 The n e w e ng l a n d j o u r na l
procedure that results in the occlusion of the
perifibroid vessels and ischemic infarction of
the fibroid.11 The treated fibroids shrink over the
course of several months to years.12 As a result,
symptoms associated with the presence and
growth of the fibroids are reduced. Incompletely
infarcted fibroids may increase in size again; new
fibroids may also develop over time.12,13 However,
in general, a successfully treated fibroid will be
permanently devascularized. Pathological studies
of uteruses after embolization typically show hya-
line necrosis or coagulative necrosis of the tumor
mass.14,15
Since 1997, when uterine fibroid embolization
was introduced into practice in the United States,16
a number of large observational studies have been
performed.17-21 These studies have shown that
menorrhagia is improved in 85 to 95% of pa-
tients, and similar rates of improvement have
been noted with respect to pelvic pain, pressure,
and urinary symptoms.
The Uterine Artery Embolization (UAE) versus
Hysterectomy for Uterine Fibroids trial (EMMY;
ClinicalTrials.gov number, NCT00100191) was a
multicenter, randomized trial in which uterine
fibroid embolization was compared with hysterec-
tomy among 177 patients in the Netherlands.22,23
Patients in the embolization group had a more
rapid recovery and a shorter hospital stay than
those in the hysterectomy group (2.7 vs. 5.1 days
in the hospital), but were more often readmitted
to the hospital (11.1% vs. 0%). Both groups had
substantial and similar improvements in health-
related quality of life, and similar proportions
of patients considered themselves to be at least
“moderately satisfied” with the outcome at 24
months (92% in the embolization group and 90%
in the hysterectomy group). Patients who had
undergone a hysterectomy were more often “very
satisfied” with the outcome than those who had
undergone embolization (45% vs. 34%), and 24%
of the patients who had undergone embolization
had a recurrence of symptoms that subsequently
necessitated a hysterectomy.
The Randomized Trial of Embolization versus
Surgical Treatment for Fibroids (REST; Current
Controlled Trials number, ISRCTN23023665) was
a multicenter study of 157 patients in the United
Kingdom who were randomly assigned to either
surgery (hysterectomy or myomectomy) or em-
bolization.24 The investigators found no differ-
ences in health-related quality of life between the
692 n engl j med 361;7  nejm.org  august 13, 2009
The New England Journal of Medicine
Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
of m e dic i n e
two groups after treatment, although women in
the surgical group reported a greater reduction
in symptoms. More major adverse events occurred
in the surgical group than in the embolization
group during the initial hospital stay, whereas
the reverse was true after discharge. With a me-
dian follow-up of 32 months, the likelihood of
reintervention was much higher among the pa-
tients who underwent embolization than among
those who underwent surgery (20% vs. 2%,
P<0.001). Ten interventions occurred among pa-
tients in the embolization group in the first year,
presumably owing to a failure of embolization to
relieve symptoms, and 11 occurred during the
subsequent follow-up period. Another long-term
study showed that by 5 years after treatment, 20%
of patients who had undergone embolization re-
quired reintervention.25
T r e atmen t
Treatment for uterine fibroids is generally indi-
cated only when symptoms are present that are
severe enough to be unacceptable to the patient.
There is no evidence that women with no symp-
toms or with mild symptoms benefit from inter-
vention. Exceptions may include women with
severe anemia or with hydronephrosis due to ure-
teral obstruction.26,27
Medical therapy is useful in some patients
with symptomatic fibroids. Acetaminophen and
nonsteroidal antiinflammatory drugs (NSAIDs)
are often effective for the relief of pain associ-
ated with fibroids, although these drugs do not
reduce bleeding. A variety of hormonal therapies,
including androgenic steroids, mifepristone, and
gonadotropin-releasing hormone agonists and
antagonists, have been shown to reduce uterine
volume and bleeding. However, most of these
treatments have not been evaluated in random-
ized trials, and in many cases the benefits of
hormonal therapy do not appear to be sustained
over the long term.26,27 In addition, many patients
do not want to consider taking hormonal therapy
or do not tolerate it well.
For patients requiring interventional treatment,
the principal current options include hysterec-
tomy, myomectomy, endometrial ablation (when
menorrhagia is the primary indication and en-
dometrial anatomy is appropriate), and uterine
fibroid embolization. Selection among these pro-
cedures depends on the patient’s age, symptoms,
 clinical ther apeutics
coexisting conditions, and reproductive plans,
as well as the specific characteristics of the fi­
broids.26,27 A thoughtful discussion of the op-
tions with an experienced specialist is essential
in choosing the most appropriate treatment for
a given patient.
Uterine fibroid embolization is a reasonable
option for most patients in whom intervention is
considered to be appropriate. There is some evi-
dence that patients with larger single fibroids
and larger uteruses may have less improvement
and less satisfaction with the results20,28; in our
experience, most patients will have substantial
improvement if the size of the uterus on exami-
nation before the procedure is no larger than the
size of the uterus at 22 to 24 weeks’ gestation
(2 to 4 cm above the umbilicus). There are some
fibroids with locations or morphologic features
that appear to make them less-than-ideal candi-
dates for embolization, including broad-ligament
fibroids, cervical fibroids, narrow-based peduncu-
lated fibroids, and intracavitary fibroids. How-
ever, this perception is based primarily on clini-
cal experience, and little evidence from systematic
studies is available to support it.
There are few contraindications to uterine fi-
broid embolization. Pregnancy, suspected pelvic
cancer, active infection, or indeterminate endo-
metrial or adnexal abnormalities requiring fur-
ther evaluation are clear contraindications. The
procedure may be performed in many patients
who might be poor risks for surgery, including
women who are obese, those who have had pre-
vious pelvic surgery, and those who have severe
anemia or other major coexisting conditions.
Uterine fibroid embolization does not appear to
be the most appropriate choice for women who
wish to become pregnant in the future (see Areas
of Uncertainty).
All women should undergo a thorough gyne-
cologic evaluation and pelvic examination before
the procedure. In addition, imaging of the uter-
us by ultrasonography or MRI is necessary to
evaluate the size, location, and number of fi-
broids. Laboratory tests that are performed be-
fore the procedure typically include a complete
blood count, coagulation studies, a metabolic
panel, and a pregnancy test.
Uterine fibroid embolization should be per-
formed by an appropriately trained and experi-
enced professional, usually an interventional radi­
ologist.29,30 The procedure is a percutaneous
n engl j med 361;7  nejm.org  august 13, 2009
The New England Journal of Medicine
Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
angiographic technique performed in a radio-
graphic suite with the use of video fluoroscopic
imaging. The patient is usually sedated during
the procedure. A small-bore primary angiograph-
ic catheter is inserted into the common femoral
artery and is advanced with the use of a guide-
wire over the aortic bifurcation and into the op-
posite hypogastric artery. The primary catheter
or a smaller-bore microcatheter placed through
the primary catheter is then advanced into the
uterine artery and typically placed in the distal
transverse artery. An arteriogram is obtained to
visualize the anatomy of the arterial plexus sup-
plying the fibroid (Fig. 2A). Embolization is then
performed with the use of particulate emboliza-
tion material. Commonly used embolic agents
include polyvinyl alcohol particles, trisacryl gela-
tin microspheres, and gelatin sponge. The embo-
lic material is injected and is carried by the arte-
rial blood flow to the vessels feeding the fibroid.
These vessels are preferentially occluded since
they are larger and have a higher flow than nor-
mal myometrial branches. The procedure is ter-
minated when the fibroid blood supply is oc-
cluded but there is still sluggish flow in the
uterine artery (Fig. 2B). The catheter is then
moved to the ipsilateral hypogastric artery, and
the procedure is repeated in the opposite uterine
artery. After the procedure, the patient is usually
admitted to the hospital for 1 night, for observa-
tion, often on a designated interventional radiol-
ogy service.
For several hours after the procedure, most
patients have moderate to intense pelvic pain that
requires treatment with intravenous narcotics and
NSAIDs. In one study, the mean score for severity
of pain on a visual-analogue scale that ranged
from 0 to 10, in which higher numbers indicat­
ed greater pain, was 3 during the first 24 hours
and 4.9 during the first week after treatment.31
However, the severity can vary considerably; about
20% of women had a score on the visual-analogue
scale of more than 7 during the first week. Pa-
tients also typically have malaise, fatigue, and
myalgias for several days. About a third of pa-
tients have a mild fever, with only 2% having a
temperature of more than 38.5°C. Most patients
return to work and other normal activities within
7 to 14 days after the procedure.
Many patients will have light vaginal bleed-
ing, spotting, or a brownish vaginal discharge for
several days, often until the first menstrual cycle.
693
 The n e w e ng l a n d j o u r na l of m e dic i n e

Figure 2. Uterine Fibroid Embolization.

A Panel A shows the perfusion of a uterine fibroid before
embolization. Two vascular catheters are shown, insert-
ed through the left and right femoral arteries and cross-
ing to the contralateral internal iliac arteries. The tips
of these catheters are marked with white arrows. Micro-
catheters are inserted through the bore of the primary
catheters and are advanced to the distal transverse
uterine artery. The tips of these microcatheters are
marked with black arrows. The blood supply of the
­f ibroid (the spherical structure indicated by the white
­arrowhead) is provided primarily through enlarged cir-
cumferential branches from the left and right uterine
arteries. The more uniform intense contrast enhance-
ment on the right is typical of normal myometrium.
­Although the embolization procedure is usually per-
formed with sequential, rather than simultaneous,
catheterization of the two uterine arteries, this image
shows the bilateral nature of fibroid perfusion. Panel B
shows the same uterine fibroid after embolization. The
tips of the primary catheters (white arrows) and micro-
catheters (black arrows) are unchanged. The arterial
branches supplying the fibroid tumor have been occluded
B by embolic material injected through the microcatheters.

embolization was $8,293. This figure included

hospital and physician charges.34 The mean total
cost over the first year was $13,270; this amount
included subsequent procedures, imaging, medi-
cations, and hospital and office visits.

Adverse Effects
In a registry of 3160 women undergoing uterine
fibroid embolization, major complications (as de-
fined by the Society of Interventional Radiology
Clinical Practice Guidelines) occurred in 0.66%
of registrants during the initial hospitalization
and in 4.8% during the first month after the pro-
cedure.21 More than half of these complications
consisted of persistent or recurrent pain or nau-
sea. In a single-center study of 400 consecutive
patients, the event rate for major complications
There may be some short-term menstrual irregu- was 4.3% during the first year.35
larity, but most women will resume regular men- The most common constellation of symptoms
strualICMcycles within
AUTHOR 2 to 3 monthsRETAKE
Goodwin after treat-
1st during recovery is postembolization syndrome,
Fig 2 a,b
ment. REGAmong
F FIGURE patients who had had menorrhagia 2nd
which consists of pelvic pain, fever, and malaise.
CASE 3rd
before the procedure, menstrual bleeding
TITLE Revisedis usu- The syndrome can usually be managed with
EMail Line 4-C
ally Enon
reduced by the
ARTIST: mleahy
second or third menstrual
SIZE analgesics and antipyretic agents, although more
H/T
32 Pelvic pain, dysmenorrhea, H/T
cycle.FILL Combo pressure,
16p6 and severe symptoms may require prolonged hospi-
urinary symptoms are reduced
AUTHOR, on a similar time-
PLEASE NOTE: talization or rehospitalization. It is important to
Figure has been redrawn and type has been reset.
table, and by 3 months after the procedure, most
Please check carefully.
distinguish this syndrome from infection, which
patients will have relief of symptoms.19,33 is a less common complication, but one that can
InJOB:
a study
36107in which data were ISSUE:collected
08-13-09 from be serious.
the database of several national claims payers in No deaths have been reported in any of the
the United States, the mean cost of uterine fibroid large clinical studies.19,21,35,36 There have been

694 n engl j med 361;7  nejm.org  august 13, 2009

The New England Journal of Medicine

Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
 clinical ther apeutics
two case reports of death due to infection.37,38
One letter to the editor describes a death due to
systemic nontarget embolization in a woman
with uterine arteriovenous shunting and patent
foramen ovale.39 Although there are no other pub-
lished reports of deaths, we are aware of an
unpublished report of one death due to a pulmo-
nary embolus.40
Pulmonary embolism was reported to occur
in 1 in 300 patients in one study.41 This phenom-
enon appears to be related to transient hyperco-
agulability — similar to that seen after surgery,
although usually less severe.42
Transcervical expulsion of a fibroid or of fi-
broid tissue occurs in 2.2 to 7.7% of women after
uterine fibroid embolization, and in some cases
surgical extraction may be necessary.36 Fibroid
expulsion can be associated with endometrial or
fibroid infection, although not invariably. Minor
infection, whether in the context of fibroid pas-
sage or not, occurs in approximately 5.9% of pa-
tients, whereas major infection, sometimes neces-
sitating surgery, occurs in 2.6% of patients.36
Prophylactic antibiotics are routinely adminis-
tered during embolization to reduce the risk of
subsequent infection.43
Transient or permanent amenorrhea has been
reported as a result of partial nontarget embo-
lization of the ovaries and subsequent reduction
in ovarian reserve. Amenorrhea is seen in 2 to 5%
of women; permanent amenorrhea occurs in less
than 2% of women, nearly all of whom are of
perimenopausal age.36 Other nontarget embolic
complications have been very rare and include
damage to the buttock44 or to the bladder or ad-
jacent structures.45,46
A r e a s of Uncer ta in t y
The primary unresolved question with respect to
uterine fibroid embolization is its effect on fu-
ture pregnancy. It was mentioned above that
ovarian function may infrequently be impaired
after the procedure. It might also be anticipated
that embolization could influence the endome-
trium and embryo implantation, as well as the
course of pregnancy. In one series of 56 pregnan-
cies after embolization, 17 ended in miscarriage.
Of the 33 live deliveries, 24 were by caesarean
section. There were 6 cases of postpartum hem-
orrhage.47 Placental abnormalities such as placenta
previa or placenta accreta may contribute to an
n engl j med 361;7  nejm.org  august 13, 2009
The New England Journal of Medicine
Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
increased risk of bleeding and may, in some cases,
lead to hysterectomy.48
Recently published data from a randomized
study involving women in Prague, Czech Repub-
lic, provide a basis for comparison of the effect
of embolization and myomectomy on reproduc-
tion. The investigators enrolled 121 patients, 63
of whom were randomly assigned to myomec-
tomy and 58 to embolization.49 At the time of
the report, 40 women had tried to conceive after
myomectomy and 26 after embolization. As com-
pared with women who had undergone myomec-
tomy, women who had undergone embolization
had a higher relative risk of not conceiving (rela-
tive risk with embolization, 2.22) and of having a
spontaneous abortion (relative risk, 2.79). These
results favor myomectomy for women who are
interested in conceiving in the short term (up to
2 years after the procedure). Longer-term out-
comes with respect to reproduction are not yet
available.
Guidel ine s
The American College of Obstetricians and Gyne-
cologists (ACOG) concludes “based on good and
consistent evidence (level A)” that “uterine artery
embolization is a safe and effective option for
appropriately selected women who wish to retain
their uteri.”50 The ACOG also recommends cau-
tion when considering embolization in women
who desire to retain their ability to conceive, be-
cause age-related amenorrhea can occur in a
small minority of patients and because there is a
possibility of abnormal placentation. The Society
of Interventional Radiology and the Cardiovas-
cular and Interventional Radiological Society of
Europe state that uterine artery embolization “is
indicated for the presence of uterine leiomyoma-
ta that are causing significant lifestyle-altering
symptoms, specifically mass effect on the bladder
or intestines, and/or dysfunctional uterine bleed-
ing that is prolonged, associated with severe dys-
menorrhea, or is causing severe anemia.”51
C onclusions a nd
R ec om mendat ions
The patient described in this vignette has symp-
toms that are clearly referable to her fibroids,
and the fibroids are anatomically appropriate for
treatment with embolization. She does not have
695
 The n e w e ng l a n d j o u r na l of m e dic i n e

any contraindications to the procedure. She is not
interested in having more children and is seeking
a less invasive treatment than hysterectomy.
It is important that the patient have the op-
portunity to discuss her treatment options with a
physician who can explain the relative risks and
benefits (ideally with an expert who has experi-
ence with the clinical outcomes). Since her symp-
toms have been steadily worsening for 10 years,
it is unlikely that conservative therapy will be ac-
ceptable to her, but this option should be men-
tioned. Hormonal therapies may also be appro-
priate to discuss, although it is not clear that
they provide sustained benefit. In selecting be-
tween hysterectomy and embolization, the patient
should be told that recovery is more rapid and
early complications are fewer with embolization,
but that she has approximately a 20 to 25%
chance of requiring subsequent invasive inter-
vention. For this patient, who would like to avoid
hysterectomy, uterine fibroid embolization would
be an appropriate choice.
No potential conflict of interest relevant to this article was
reported.

References
1. Chen CR, Buck GM, Courey NG, Perez
KM, Wactawski-Wende J. Risk factors for
uterine fibroids among women undergo-
ing tubal sterilization. Am J Epidemiol
2001;153:20-6.
2. Cramer SF, Patel A. The frequency of
uterine leiomyomas. Am J Clin Pathol
1990;94:435-8.
3. Wise LA, Palmer JR, Harlow BL, et al.
Reproductive factors, hormonal contracep-
tion, and risk of uterine leiomyomata in
African-American women: a prospective
study. Am J Epidemiol 2004;159:113-23.
4. Day Baird D, Dunson DB, Hill MC,
Cousins D, Schectman JM. High cumula-
tive incidence of uterine leiomyoma in
black and white women: ultrasound evi-
dence. Am J Obstet Gynecol 2003;188:
100-7.
5. Wise LA, Palmer JR, Stewart EA,
Rosenberg L. Age-specific incidence rates
for self-reported uterine leiomyomata in
the Black Women’s Health Study. Obstet
Gynecol 2005;105:563-8.
6. Marshall LM, Spiegelman D, Barbieri
RL, et al. Variation in the incidence of
uterine leiomyoma among premenopausal
women by age and race. Obstet Gynecol
1997;90:967-73.
7. Flynn M, Jamison M, Datta S, Myers E.
Health care resource use for uterine fi-
broid tumors in the United States. Am J
Obstet Gynecol 2006;195:955-64.
8. Parker WH. Etiology, symptomatology,
and diagnosis of uterine myomas. Fertil
Steril 2007;87:725-36.
9. Walker CL, Stewart EA. Uterine fi-
broids: the elephant in the room. Science
2005;308:1589-92.
10. Pelage J-P, Cazejust J, Pluot E, et al.
Uterine fibroid vascularization and clini-
cal relevance to uterine fibroid emboliza-
tion. Radiographics 2005;25:Suppl 1:S99-
S117.
11. McCluggage WG, Ellis PK, McClure N,
Walker WJ, Jackson PA, Manek S. Patho-
logic features of uterine leiomyomas fol-
lowing uterine artery embolization. Int J
Gynecol Pathol 2000;19:342-7.
12. Pelage JP, Guaou Guaou N, Jha R, As-
cher S, Spies J. Uterine fibroid tumors:
long-term MR imaging outcome after em-
bolization. Radiology 2004;230:803-9.
13. Yousefi S, Czeyda-Pommersheim F,
White AM, Banovac F, Hahn WY, Spies JB.
Repeat uterine artery embolization: indi-
cations and technical findings. J Vasc In-
terv Radiol 2006;17:1923-9.
14. Colgan TJ, Pron G, Mocarski EJM,
Bennett JD, Asch MR, Common A. Patho-
logic features of uteri and leiomyomas
following uterine artery embolization for
leiomyomas. Am J Surg Pathol 2003;27:
167-77.
15. Weichert W, Denkert C, Gauruder-
Burmester A, et al. Uterine arterial em-
bolization with tris-acryl gelatin micro-
spheres: a histopathologic evaluation. Am
J Surg Pathol 2005;29:955-61.
16. Goodwin SC, Vedantham S, McLucas
B, Forno AE, Perrella R. Preliminary expe-
rience with uterine artery embolization
for uterine fibroids. J Vasc Interv Radiol
1997;8:517-26. [Erratum, J Vasc Interv Ra-
diol 1999;10:991.]
17. Goodwin SC, Spies JB, Worthington-
Kirsch R, et al. Uterine artery emboliza-
tion for treatment of leiomyomata: long-
term outcomes from the FIBROID Registry.
Obstet Gynecol 2008;111:22-33.
18. Pelage JP, Jacob D, Fazel A, et al. Mid-
term results of uterine artery emboliza-
tion for symptomatic adenomyosis: initial
experience. Radiology 2005;234:948-53.
19. Pron G, Bennett J, Common A, Wall J,
Asch M, Sniderman K. The Ontario Uter-
ine Fibroid Embolization Trial. 2. Uterine
fibroid reduction and symptom relief after
uterine artery embolization for fibroids.
Fertil Steril 2003;79:120-7.
20. Spies J, Myers ER, Worthington-Kirsch
R, Mulgund J, Goodwin S, Mauro M. The
FIBROID Registry: symptom and quality-
of-life status 1 year after therapy. Obstet
Gynecol 2005;106:1309-18.
21. Worthington-Kirsch R, Spies J, Myers
E, et al. The Fibroid Registry for Out-
comes Data (FIBROID) for uterine artery
embolization: short-term outcomes. Ob-
stet Gynecol 2005;106:52-9. [Erratum, Ob-
stet Gynecol 2005;106:869.]
22. Hehenkamp WJ, Volkers NA, Birnie E,
Reekers JA, Ankum WM. Symptomatic
uterine fibroids: treatment with uterine
artery embolization or hysterectomy —
results from the randomized clinical Em-
bolisation versus Hysterectomy (EMMY)
Trial. Radiology 2008;246:823-32.
23. Hehenkamp WJ, Volkers NA, Donder-
winkel PF, et al. Uterine artery emboliza-
tion versus hysterectomy in the treatment
of symptomatic uterine fibroids (EMMY
trial): peri- and postprocedural results
from a randomized controlled trial. Am J
Obstet Gynecol 2005;193:1618-29.
24. The REST Investigators. Uterine-artery
embolization versus surgery for symp-
tomatic uterine fibroids. N Engl J Med
2007;356:360-70.
25. Spies JB, Bruno J, Czeyda-Pommer-
sheim F, Magee ST, Ascher SA, Jha RC.
Long-term outcome of uterine artery em-
bolization of leiomyomata. Obstet Gyne-
col 2005;106:933-9.
26. Parker WH. Uterine myomas: manage-
ment. Fertil Steril 2007;88:255-71.
27. Stewart EA. Uterine fibroids. Lancet
2001;357:293-8.
28. Spies J, Roth AR, Jha RA, et al. Leio-
myomata treated with uterine artery em-
bolization: factors associated with success-
ful symptomatic and imaging outcome.
Radiology 2002;222:45-52.
29. Lefebvre GG, Vilos G, Asch M. Uterine
fibroid embolization (UFE). J Obstet Gy-
naecol Can 2004;26:899-911, 913-28.
30. Spies J, Niedzwiecki G, Goodwin S,
et al. Training standards for physicians
performing uterine artery embolization
for leiomyomata: consensus statement de-
veloped by the Task Force on Uterine Ar-
tery Embolization and the standards divi-
sion of the Society of Cardiovascular &
Interventional Radiology — August 2000.
J Vasc Interv Radiol 2001;12:19-21.
31. Bruno J, Sterbis K, Flick P, et al. Re-
covery after uterine artery embolization

696 n engl j med 361;7  nejm.org  august 13, 2009

The New England Journal of Medicine

Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.
 clinical ther apeutics

for leiomyomas: a detailed analysis of its
duration and severity. J Vasc Interv Radiol
2004;15:801-7.
32. Khaund A, Moss JG, McMillan N,
Lumsden MA. Evaluation of the effect of
uterine artery embolisation on menstrual
blood loss and uterine volume. BJOG 2004;
111:700-5.
33. Spies JB, Ascher SA, Roth AR, Kim J,
Levy EB, Gomez-Jorge J. Uterine artery
embolization for leiomyomata. Obstet
Gynecol 2001;98:29-34.
34. Dembek CJ, Pelletier EM, Isaacson KB,
Spies JB. Payer costs in patients undergo-
ing uterine artery embolization, hyster-
ectomy, or myomectomy for treatment of
uterine fibroids. J Vasc Interv Radiol 2007;
18:1207-13.
35. Spies JB, Spector A, Roth AR, Baker
CM, Mauro L, Murphy-Skrynarz K. Com-
plications after uterine artery emboliza-
tion for leiomyomas. Obstet Gynecol 2002;
100:873-80.
36. Dutton S, Hirst A, McPherson K, Nich-
olson T, Maresh MA. A UK multicentre
retrospective cohort study comparing
hysterectomy and uterine artery emboli-
sation for the treatment of symptomatic
uterine fibroids (HOPEFUL study): main
results on medium-term safety and effi-
cacy. BJOG 2007;114:1340-51.
37. de Blok S, de Vries C, Prinssen HM,
Blaauwgeers HL, Jorna-Meijer LB. Fatal
sepsis after uterine artery embolization
with microspheres. J Vasc Interv Radiol
2003;14:779-83.
38. Vashisht A, Studd J, Carey A, Burn P.
Fatal septicaemia after fibroid embolisa-
tion. Lancet 1999;354:307-8.
39. Fatal nontarget embolization via an
intrafibroid arterial venous fistula during
uterine fibroid embolization. J Vasc Interv
Radiol 2009;20:419-20.
40. Lanocita R, Frigerio L, Patelli G, Di
Tolla G, Spreafico C. A fatal complication
of percutaneous transcatheter emboliza-
tion for treatment of uterine fibroids. Pre-
sented at the SMIT/CIMIT 11th Annual
Scientific Meeting, Boston, September
16–18, 1999. abstract.
41. Czeyda-Pommersheim F, Magee ST,
Cooper C, Hahn WY, Spies JB. Venous
thromboembolism after uterine fibroid
embolization. Cardiovasc Intervent Radi-
ol 2006;29:1136-40.
42. Nikolic B, Kessler CM, Jacobs HM, et
al. Changes in blood coagulation markers
associated with uterine artery emboliza-
tion for leiomyomata. J Vasc Interv Radiol
2003;14:1147-53.
43. Hirst A, Dutton S, Wu O, et al. A
multi-centre retrospective cohort study
comparing the efficacy, safety and cost-
effectiveness of hysterectomy and uterine
artery embolisation for the treatment of
symptomatic uterine fibroids: the HOPE-
FUL study. Health Technol Assess 2008;
12:1-248.
44. Dietz DM, Stahlfeld KR, Bansal SK,
Christopherson WA. Buttock necrosis af-
ter uterine artery embolization. Obstet
Gynecol 2004;104:1159-61.
45. El-Shalakany AH, Nasr El-Din MH,
Wafa GA, Azzam ME, El-Dorry A. Massive
vault necrosis with bladder fistula after
uterine artery embolisation. BJOG 2003;
110:215-6.
46. Sultana CJ, Goldberg J, Aizenman L,
Chon JK. Vesicouterine fistula after uter-
ine artery embolization: a case report. Am
J Obstet Gynecol 2002;187:1726-7.
47. Walker WJ, McDowell SJ. Pregnancy
after uterine artery embolization for leio-
myomata: a series of 56 completed preg-
nancies. Am J Obstet Gynecol 2006;195:
1266-71.
48. Pron G, Mocarski E, Bennett J, et al.
Pregnancy after uterine artery emboliza-
tion for leiomyomata: the Ontario multi-
center trial. Obstet Gynecol 2005;105:67-
76.
49. Mara M, Maskova J, Fucikova Z, Kuzel
D, Belsan T, Sosna O. Midterm clinical
and first reproductive results of a ran-
domized controlled trial comparing uter-
ine fibroid embolization and myomecto-
my. Cardiovasc Intervent Radiol 2008;31:
73-85.
50. American College of Obstetricians and
Gynecologists. ACOG practice bulletin:
alternatives to hysterectomy in the man-
agement of leiomyomas. Obstet Gynecol
2008;112:387-400.
51. Hovsepian DM, Siskin GP, Bonn J, et al.
Quality improvement guidelines for uter-
ine artery embolization for symptomatic
leiomyomata. Cardiovasc Intervent Radiol
2004;27:307-13.
Copyright © 2009 Massachusetts Medical Society.

collections of articles on the journal’s web site

The Journal’s Web site (NEJM.org) sorts published articles into
more than 50 distinct clinical collections, which can be used as convenient
entry points to clinical content. In each collection, articles are cited in reverse
chronologic order, with the most recent first.

n engl j med 361;7  nejm.org  august 13, 2009 697

The New England Journal of Medicine
Downloaded from nejm.org at Hinari Phase 1 sites -- comp on May 9, 2011. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.